Eosinophilic Esophagitis Treatment Market Size in the 7MM was ~USD 1,800 million in the 2023, which is expected to grow by 2034, estimates DelveInsight

DelveInsight's "Eosinophilic Esophagitis Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Eosinophilic Esophagitis historical and forecasted epidemiology as well as the Eosinophilic Esophagitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Eosinophilic Esophagitis Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Eosinophilic Esophagitis Market Size [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Eosinophilic Esophagitis Market Report

* In June 2025, Sanofi announced a Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis.
* In June 2025, Dr. Falk Pharma GmbH conducted a study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
* In the 7MM, the US accounted for the highest Eosinophilic Esophagitis Diagnosed Prevalent Cases in 2023, with around 445,000 cases; these numbers are expected to increase during the forecast period.
* Eosinophilic Esophagitis predominantly affected males, with approximately 290,000 males diagnosed compared to 156,000 females in 2023 in the US.
* In the 7MM, individuals over the age of 18 were the most affected by Eosinophilic Esophagitis, with approximately 156,000 cases reported in 2023.
* The leading Eosinophilic Esophagitis Companies such as Bristol Myers Squibb (BMS), Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Dr. Falk Pharma GmbH, Regeneron Pharmaceuticals, Sanofi, Allakos, Pfizer, Revolo Biotherapeutics, EsoCap AG, and others.
* Promising Eosinophilic Esophagitis Pipeline Therapies such as Mepolizumab, Dupilumab, Etrasimod, Tezepelumab, Barzolvolimab, NDX-3315 and NDX-3324 and others.

Stay ahead in the competitive landscape of the Eosinophilic Esophagitis Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Eosinophilic Esophagitis Treatment Market Size [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Eosinophilic Esophagitis Epidemiology Segmentation in the 7MM

* Total Diagnosed Prevalent Cases of Eosinophilic Esophagitis
* Gender-specific Cases of Eosinophilic Esophagitis
* Age-specific Cases of Eosinophilic Esophagitis
* Treated Cases of Eosinophilic Esophagitis

Download the report to understand which factors are driving Eosinophilic Esophagitis epidemiology trends @ Eosinophilic Esophagitis Prevalence [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Eosinophilic Esophagitis Marketed Drugs

* DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals

DUPIXENT, which was invented using Regeneron's proprietary VelocImmune technology, is a fully human monoclonal antibody that inhibits the signaling of the Interleukin-4 (IL-4) and Interleukin-13 (IL-13) pathways and is not an immunosuppressant. It is approved for the treatment of DUPIXENT, which was invented using Regeneron's proprietary VelocImmune technology, is a fully human monoclonal antibody that inhibits the signaling of the Interleukin-4 (IL-4) and Interleukin-13 (IL-13) pathways and is not an immunosuppressant.

Eosinophilic Esophagitis Emerging Drugs

* Cendakimab (CC-93538/RPC4046): Bristol Myers Squibb (BMS)

Cendakimab/RPC4046/CC-93538 is a recombinant humanized, high affinity, selective, anti-IL-13 mAb. RPC4046 binds an IL-13 epitope that prevents its binding to both IL-13R (alpha) 1 and IL-13R (alpha) 2, providing potential efficacy and/or safety advantages. The drug has been granted ODD for the treatment of EoE by the US FDA. In the Phase II study, RPC4046 demonstrated positive results. Currently, the company is conducting two Phase III Eosinophilic Esophagitis clinical trials to evaluate the efficacy and safety of CC-93538 in adult and adolescent participants with EoE.

* TEZSPIRE (Tezepelumab) : AstraZeneca/Amgen

TEZSPIRE (tezepelumab) is being developed by AstraZeneca in collaboration with Amgen as a first-in-class human monoclonal antibody that inhibits the action of TSLP. This key epithelial cytokine sits at the top of multiple inflammatory cascades. It is critical in the initiation and persistence of allergic, eosinophilic, and other types of airway inflammation associated with severe asthma, including airway hyperresponsiveness. TEZSPIRE acts at the top of the inflammation cascade and has the potential to help address a broad population of severe asthma patients irrespective of biomarker levels.

Discover the future of Eosinophilic Esophagitis Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Eosinophilic Esophagitis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Eosinophilic Esophagitis Market Outlook

The Eosinophilic Esophagitis Market is driven by significant unmet needs, particularly in the development of novel treatments and the establishment of comprehensive guidelines for adolescents and adults. Current treatments, like proton pump inhibitors and corticosteroids therapy, manage symptoms but come with serious side effects due to high steroid dosages. Although in recent years therapies like DUPIXENT, EOHILIA and JOrveza got approved in 7MM countries but still there is huge scope for emerging.

Eosinophilic Esophagitis Companies

Bristol Myers Squibb (BMS), Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Dr. Falk Pharma GmbH, Regeneron Pharmaceuticals, Sanofi, Allakos, Pfizer, Revolo Biotherapeutics, EsoCap AG, and others.

Scope of the Eosinophilic Esophagitis Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Eosinophilic Esophagitis Companies- Bristol Myers Squibb (BMS), Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Dr. Falk Pharma GmbH, Regeneron Pharmaceuticals, Sanofi, Allakos, Pfizer, Revolo Biotherapeutics, EsoCap AG, and others.
* Eosinophilic Esophagitis Pipeline Therapies- Mepolizumab, Dupilumab, Etrasimod, Tezepelumab, Barzolvolimab, NDX-3315 and NDX-3324 and others.
* Eosinophilic Esophagitis Therapeutic Assessment: Eosinophilic Esophagitis Current Marketed and Eosinophilic Esophagitis Emerging Therapies
* Eosinophilic Esophagitis Market Dynamics: Eosinophilic Esophagitis market drivers and Eosinophilic Esophagitis market barriers
* Eosinophilic Esophagitis Unmet Needs, KOL's views, Analyst's views, Eosinophilic Esophagitis Market Access and Reimbursement

Explore the dynamics of the Eosinophilic Esophagitis Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Eosinophilic Esophagitis Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

1. Key Insights

2. Eosinophilic Esophagitis Market Report Introduction

3. Eosinophilic Esophagitis Market Overview at a Glance

4. Eosinophilic Esophagitis Methodology

5. Eosinophilic Esophagitis Executive Summary

6. Key Events

7. Disease Background and Overview

8. Eosinophilic Esophagitis Treatment

9. Treatment Guidelines

10. Eosinophilic Esophagitis Epidemiology and Patient Population

11. Patient Journey

12. Eosinophilic Esophagitis Marketed Therapies

13. Eosinophilic Esophagitis Emerging Therapies

14. Eosinophilic Esophagitis Market Analysis

15. KOL Views

16. Eosinophilic Esophagitis SWOT Analysis

17. Eosinophilic Esophagitis Unmet Needs

18. Market Access and Reimbursement

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=eosinophilic-esophagitis-treatment-market-size-in-the-7mm-was-usd-1800-million-in-the-2023-which-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.